Journal of Clinical Advances and Research Reviews (JCARR)
Website: http://www.jcarr.in/
ISSN: 3048-6556
Vol. 3, Issue 1, Jan-Mar, 2026
Page No.: 11-12

Short-Communication

Role of Systemic Inflammation in Chronic Diseases and Cancer: Clinical Perspectives and Research Advances

Mukesh Kumar, Subham Mandal

Department of Pharmacy, IIMT College of Medical Sciences, IIMT University, O-Pocket, Ganganagar, Meerut, U.P., 250001, India

Received: 01-01-2026 / **Revised:** 06-02-2026 / **Accepted:** 08-03-2026
Corresponding Author: Subham Mandal
DOI: 10.62896/jcarr.3.1.04
Email: sk8006721807@gmail.com
Conflict of interest: Nil

Abstract:
Systemic inflammation is a common thread weaving through the pathogenesis of diverse chronic conditions, ranging from cardiovascular diseases and metabolic disorders to malignancy. Characterized by the persistent activation of innate immune signaling pathways and the elevation of circulating pro-inflammatory cytokines, systemic inflammation acts as both a driver and a consequence of tissue damage. This manuscript reviews the physiological underpinnings of "meta-inflammation," the molecular crosstalk between inflammatory mediators and tumor biology, and the clinical utility of hematological markers like the **Neutrophil-to-Lymphocyte Ratio (NLR)**. We discuss translational research advances that highlight inflammation as a therapeutic target, aiming to move toward precision-based anti-inflammatory interventions.
Keywords: Chronic Diseases, Cancer, Clinical Perspectives

1. Introduction

In contrast to acute inflammation, which is a self-limiting response to injury or infection, chronic systemic inflammation is a low-grade, persistent state that disrupts homeostatic balance [1]. It is increasingly recognized as a hallmark of "inflammaging" and a precursor to the most prevalent non-communicable diseases of the 21st century.

The systemic inflammatory response is mediated by a complex network of signaling molecules, including **C-reactive protein (CRP)**, **Interleukin-6 (IL-6)**, and **Tumor Necrosis Factor-alpha (TNF-alpha)**. When these signals remain elevated, they facilitate cellular transformations, insulin resistance, and endothelial dysfunction [2].

2. Inflammation in Chronic Non-Communicable Diseases

2.1 Cardiovascular and Metabolic Disorders

In atherosclerosis, systemic inflammation facilitates the recruitment of leukocytes to the vascular endothelium, promoting plaque formation and eventual rupture. Similarly, obesity-induced inflammation—often termed **meta-inflammation**—originates in adipose tissue where hypertrophic adipocytes secrete adipokines that induce systemic insulin resistance [2].

2.2 Chronic Kidney Disease (CKD)

Chronic inflammation is both a cause and a complication of CKD. Elevated inflammatory markers correlate with the progression of renal fibrosis. Recent studies suggest that the **Neutrophil-to-Lymphocyte Ratio (NLR)** is a significant predictor of all-cause mortality and major vascular events in patients with diabetic kidney disease [2].

3. The Inflammation–Cancer Nexus

The relationship between inflammation and cancer is bidirectional. Chronic inflammation can initiate oncogenesis by inducing DNA damage through the release of **reactive oxygen species (ROS)** and reactive nitrogen species.

3.1 The Tumor Microenvironment (TME)

Once a tumor is established, it highjacks inflammatory pathways to remodel the TME. Tumors recruit **Tumor-Associated Neutrophils (TANs)** and **Myeloid-Derived Suppressor Cells (MDSCs)**, which suppress the cytotoxic activity of T-lymphocytes, allowing the cancer to evade immune detection [1].

3.2 NLR as a Prognostic Tool

The NLR has emerged as a crucial peripheral biomarker in oncology. A high NLR typically indicates:

1. **Neutrophilia:** Reflecting an expanded innate immune response that supports tumor growth, angiogenesis, and metastasis.
2. **Lymphopenia:** Indicating a suppressed adaptive immune system and a reduced capacity for anti-tumor surveillance [1, 3].

4. Translational Research and Clinical Advances

4.1 Predictive Value for Metastasis

Research has shown that systemic inflammatory markers are potent predictors of site-specific metastasis. For instance, elevated pre-treatment NLR and Platelet-to-Lymphocyte Ratio (PLR) are significantly associated with a higher risk of brain metastasis in patients with lung cancer [3].

4.2 Response to Immunotherapy

In the era of **Immune Checkpoint Inhibitors (ICIs)**, monitoring systemic inflammation has become vital. High baseline inflammation often correlates with primary resistance to PD-1/PD-L1 inhibitors. Conversely, a decrease in NLR during treatment is often indicative of a favorable therapeutic response [1].

Disease Context	Primary Inflammatory Driver	Clinical Marker
Atherosclerosis	Endothelial activation / CRP	High-sensitivity CRP
Diabetes / Obesity	Adipokines / TNF-alpha	NLR / HbA1c
Solid Tumors	NETs / IL-6 / TGF-beta	NLR / PLR

5. Challenges and Future Directions

While the role of systemic inflammation is well-documented, several challenges remain:

- **Standardization:** Establishing universal "cut-off" values for markers like NLR across different ethnicities and age groups.
- **Specificity:** Inflammation is a non-specific response; distinguishing between cancer-related inflammation and comorbid infection remains difficult.
- **Targeted Therapy:** Moving beyond broad anti-inflammatories to specific cytokine inhibitors (e.g., IL-1β or IL-6 blockers) to improve cancer outcomes without compromising general immunity.

6. Conclusion

Systemic inflammation is a fundamental determinant of health and disease. By bridging the gap between basic immunology and clinical practice, markers like the NLR provide clinicians with a "window" into the host-tumor interaction. Future strategies focusing on the resolution of inflammation rather than just its suppression hold the key to managing chronic diseases and improving cancer survivorship.

References

1. **Mosca, M., Nigro, M. C., Pagani, R., De Giglio, A., & Di Federico, A. (2023).** Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond. *Biomolecules*, 13(12), 1803.
2. **Chee, Y. J., Zhang, X. X. D., & Dalan, R. (2025).** Associations between neutrophil-lymphocyte ratio with all-cause mortality, major adverse vascular events and progression of diabetic kidney disease in type 2 diabetes mellitus. *Frontiers in Endocrinology*, 16.
3. **Frontiers in Oncology. (2026).** Associations of three immune inflammatory markers with the risk of brain metastasis from lung cancer: a systematic review and meta-analysis. *Frontiers in Oncology*, 16.

*****